Oculis gains on FDA breakthrough therapy status for optic neuritis therapy
Source: SeekingAlpha
2026-01-06 11:19:30 ET
More on Oculis Holding
- Oculis Holding AG (OCS) Shareholder/Analyst Call - Slideshow
- Seeking Alpha’s Quant Rating on Oculis Holding
- Historical earnings data for Oculis Holding
- Financial information for Oculis Holding
Read the full article on Seeking Alpha
For further details see:
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy
Oculis Holding AG
NASDAQ: OCS
OCS Trading
-4.07% G/L:
$26.90 Last:
190,365 Volume:
$27.73 Open:
OCS Latest News
March 03, 2026 04:05:00 pm
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
OCS Stock Data
$1,527,387,432
49,696,926
N/A
16
N/A
Biotechnology & Life Sciences
Healthcare
CH
